ABCSG 49 Overview
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
| Study start : | (global): 08/2019 (national): 10/2020 |
| Coordinating Investigator: | Balic, Marija; Graz |
| Patient Accrual: | 400 (global), 50 (national) |
| Study Design: (Click to enlarge) |
 |
Share on